Rationale and Objectives
To investigate the predictive value of gadoxetic acid-enhanced magnetic resonance
imaging (MRI) features on the pathologic grade, microvascular invasion (MVI), and
cytokeratin-19 (CK19) expression in hepatocellular carcinomas (HCC), and to evaluate
their association with postoperative recurrence of HCC.
Materials and Methods
This retrospective study included 147 patients with surgically confirmed HCCs who
underwent gadoxetic-enhanced MRI. The lesions were evaluated quantitatively in terms
of the relative enhancement ratio (RER), and qualitatively based on imaging features
and clinical parameters. Logistic regression analyses were performed to investigate
the value of these parameters in predicting the pathologic grade, MVI, and CK19 in
HCC. Predictive factors for postoperative recurrence were determined using a Cox proportional
hazards model.
Results
Peritumoral enhancement (odds ratio [OR], 3.396; p = 0.025) was an independent predictor of high pathologic grades. Serum protein induced
by vitamin K absence or antagonist (PIVKA) level > 40 mAU/mL (OR, 3.763; p = 0.018) and peritumoral hypointensity (OR, 4.343; p = 0.003) were independent predictors of MVI. Predictors of CK19 included serum alpha-fetoprotein
(AFP) level > 400 ng/mL (OR, 4.576; p = 0.005), rim enhancement (OR, 5.493; p = 0.024), and lower RER (OR, 0.013; p = 0.011). Peritumoral hypointensity (hazard ratio [HR], 1.957; p = 0.027) and poor pathologic grades (HR, 2.339; p = 0.043) were independent predictors of recurrence.
Conclusion
We demonstrated the value of preoperative gadoxetic-enhanced MRI in predicting aggressive
pathological features of HCC. Poor pathologic grades and peritumoral hypointensity
may independently predict the recurrence of HCC.
Key Words
Abbreviations:
AFP (serum alpha-fetoprotein), AUC (area under the curve), AP (arterial phase), CI (confidence interval), C-index (Harrell's concordance index), CK19 (cytokeratin-19), DWI (diffusion-weighted imaging), E-S (Edmondson-Steiner), HBP (hepatobiliary phase), HCC (hepatocellular carcinomas), HR (Hazard ratio), ICC (Inter- and intraclass correlation coefficient), MRI (magnetic resonance imaging), MVI (microvascular invasion), OR (overall recurrence), PIVKA (Serum protein induced by vitamin K absence or antagonist), RER (relative enhancement ratio), ROC (receiver operating characteristic), ROI (Region of interest), SI (signal intensity), T2W (T2-weighted)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Academic RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
REFERENCES
- Hepatocellular carcinoma.N Engl J Med. 2019; 380: 1450-1462
- Hepatocellular carcinoma.The Lancet. 2018; 391: 1301-1314
- The basis of oncoimmunology.Cell. 2016; 164: 1233-1247
- Vascular Invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.Hepatology. 2001; 33: 1080-1086
- Tumor recurrence after liver transplantation for hepatocellular carcinoma: recurrence pathway and prognostic factors.Transplant Proc. 2007; 39: 2304-2307
- Clinicopathological predictors of poor survival and recurrence after curative resection in hepatocellular carcinoma without portal vein tumor thrombosis.Pathol Oncol Res. 2015; 21: 131-138
- Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors.Ann Surg Oncol. 2008; 15: 1375-1382
- The significance of classifying microvascular invasion in patients with hepatocellular carcinoma.Ann Surg Oncol. 2014; 21: 1002-1009
- Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma.J Gastroenterol Hepatol. 2018; 33: 347-354
- Molecular and histological correlations in liver cancer.J Hepatol. 2019; 71: 616-630
- Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Nat Rev Clin Oncol. 2015; 12: 408-424
- Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.Cancer Res. 2008; 68: 6779-6788
- CK19-positive hepatocellular carcinoma is a characteristic subtype.J Cancer. 2020; 11: 5069-5077
- Human hepatocellular carcinomas with “stemness”-related marker expression: keratin 19 expression and a poor prognosis.Hepatology. 2011; 54: 1707-1717
- Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update.Clin Mol Hepatol. 2019; 25: 245-263
- Prediction of HCC microvascular invasion with gadobenate-enhanced MRI: correlation with pathology.Eur Radiol. 2020; 30: 5327-5336
- Preoperative gadoxetic acid–enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma.J Hepatol. 2017; 67: 526-534
- Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation.BMC Cancer. 2019; 19: 364
- Can LI-RADS imaging features at gadoxetic acid-enhanced MRI predict aggressive features on pathology of single hepatocellular carcinoma?.Eur J Radiol. 2020; 132109312
- MR features based on LI-RADS identify cytokeratin 19 status of hepatocellular carcinomas.Eur J Radiol. 2019; 113: 7-14
- Imaging features of gadoxetic acid–enhanced and diffusion-weighted MR imaging for identifying cytokeratin 19-positive hepatocellular carcinoma: a retrospective observational study.Radiology. 2018; 286: 897-908
- A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid–enhanced MRI.Eur Radiol. 2020; 30: 3004-3014
- Interobserver and intraobserver variability in evaluating vascular invasion in hepatocellular carcinoma: evaluation of vascular invasion in HCC.J Gastroenterol Hepatol. 2010; 25: 1556-1561
- MRI-radiomics prediction for cytokeratin 19-positive hepatocellular carcinoma: a multicenter study.Front Oncol. 2021; 11672126
- Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery.Radiology. 2021; 300: 572-582
- Quantitative analysis of multiphase magnetic resonance images may assist prediction of histopathological grade of small hepatocellular carcinoma.Ann Transl Med. 2020; 8 (–1023): 1023
- Interobserver variability and diagnostic performance of gadoxetic acid–enhanced MRI for predicting microvascular invasion in hepatocellular carcinoma.Radiology. 2020; 297: 573-581
- Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications.J Hepatol. 2021; 74: 109-121
- Small hepatocellular carcinoma: using MRI to predict histological grade and Ki-67 expression.Clin Radiol. 2019; 74: 653.e1-653.e9
- Prediction of Sorafenib Treatment–related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation.Eur Radiol. 2019; 29: 2272-2282
- Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients.Radiology. 2018; 289: 816-830
- Higher enhancement intrahepatic nodules on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as a poor responsive marker of anti-PD-1/PD-L1 monotherapy for unresectable hepatocellular carcinoma.Liver Cancer. 2021; 10: 615-628
- Evaluating the role of hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging in predicting treatment impact of lenvatinib and atezolizumab plus bevacizumab on unresectable hepatocellular carcinoma.Cancers. 2022; 14: 827
- Nomogram development and validation to predict hepatocellular carcinoma tumor behavior by preoperative gadoxetic acid-enhanced MRI.Eur Radiol. 2021; 31: 8615-8627
- Pathologic, molecular, and prognostic radiologic features of hepatocellular carcinoma.Radiographics. 2021; 41: 21
- Clinical significance of the duality of Wnt/β-catenin signaling in human hepatocellular carcinoma.Cancers. 2022; 14: 444
- A clinical scoring system for predicting microvascular invasion in patients with hepatocellular carcinoma within the milan criteria.J Gastrointest Surg. 2019; 23: 779-787
- Progression of prothrombin induced by vitamin K absence-II in hepatocellular carcinoma.Front Oncol. 2021; 11726213
- Hepatocellular carcinoma with irregular rim-like arterial phase hyperenhancement: more aggressive pathologic features.Liver Cancer. 2019; 8: 24-40
- Biology and Significance of alpha-fetoprotein in hepatocellular carcinoma.Liver Int. 2019; 39: 2214-2229
- Uptake of gadoxetic acid in hepatobiliary phase magnetic resonance imaging and transporter expression in hypovascular hepatocellular nodules.Eur J Radiol. 2021; 138109669
- Hepatocellular carcinoma grading and recurrence prediction using T1 mapping on gadolinium-ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging.Oncol Lett. 2019; 18: 2322-2329https://doi.org/10.3892/ol.2019.10557
- Grade: a crucial predictor of recurrence and survival in hepatocellular carcinoma without microvascular invasio.Pathol - Res Pract. 2017; 213: 824-830
- Preoperative prediction for early recurrence can be as accurate as postoperative assessment in single hepatocellular carcinoma patients.Korean J Radiol. 2020; 21: 402
- Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma.J Cancer Res Clin Oncol. 2017; 143: 293-303
- Gadoxetic acid–enhanced MRI as a predictor of recurrence of HCC after liver transplantation.Eur Radiol. 2020; 30: 987-995
Article info
Publication history
Published online: December 26, 2022
Accepted:
December 8,
2022
Received in revised form:
September 1,
2022
Received:
July 20,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2022 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.